1. FDA (US Department of Health and Human Services FaDA. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH); 2009. https://www.fda.gov/media/77832/download. Accessed 1 Oct 2020.
2. Brennan PF, Strombom I. Improving health care by understanding patient preferences: the role of computer technology. J Am Med Inform Assoc. 1998;5(3):257–62. https://doi.org/10.1136/jamia.1998.0050257(Epub 1998/06/03).
3. FDA (US Department of Health and Human Services FaDA. (Draft) Guidance for industry, food and drug administration staff, and other stakeholders: patient preference information—voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling: Center for Devices and Radiological Health (CDRH), Center for Biologics Evaluation and Research (CBER); 2016. https://www.fda.gov/media/92593/download. Accessed 1 Oct 2020.
4. FDA (US Department of Health and Human Services FaDA. (Draft) Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, food and drug administration staff, and other stakeholders: Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2019. https://www.fda.gov/media/131230/download. Accessed 1 Oct 2020.
5. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530–3. https://doi.org/10.1136/bmj.320.7248.1530(Epub 2000/06/02).